JAK2 and leukemia: Cooperation of IDH1/2 mutations with JAK2 V617F in leukemic transformation was demonstrated in a study of 301 patients with PMF who progressed to the blast phase: concomitant mutations IDH and JAK2 V617F resulted in a more pronounced effect on leukemia-free survival and OS (p < 0.0001, p = 0.0002, respectively) compared to the absence of IDH mutations [35].